Leung, 2014 - Google Patents
Biophysical characterization of lipid nanoparticles containing nucleic acid polymers as produced by microfluidic mixingLeung, 2014
View PDF- Document ID
- 9836110774332149464
- Author
- Leung A
- Publication year
External Links
Snippet
Lipid nanoparticles (LNP) are currently the most advanced delivery systems for enabling siRNA to be used for therapeutic applications. However, the structure of these siRNA-LNP systems has not been well defined previously. The objective of this thesis is to determine the …
- 150000002632 lipids 0 title abstract description 331
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48792—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension
- A61K47/48815—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a colloid, emulsion, i.e. having at least a dispersed/continuous oil phase and a dispersed/continuous aqueous phase, dispersion or suspension the form being a liposome, i.e. a bilayered vesicle, having its surface modified by covalent attachment or complexation of the pharmacologically or therapeutically active agent and/or modifying agent.
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MacLachlan | Liposomal formulations for nucleic acid delivery | |
JP5388395B2 (en) | Method for producing therapeutic agent encapsulated in lipid | |
Mönkkönen et al. | Lipid fusion in oligonucleotide and gene delivery with cationic lipids | |
Hafez et al. | On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids | |
Ulrich | Biophysical aspects of using liposomes as delivery vehicles | |
Liang et al. | Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery | |
Li et al. | Acidification-induced structure evolution of lipid nanoparticles correlates with their in vitro gene transfections | |
EP1156783B1 (en) | Encapsulation of bioactive complexes in liposomes | |
Levine et al. | Preparation and characterization of liposome-encapsulated plasmid DNA for gene delivery | |
WO2007037444A1 (en) | Vector for delivering target substance into nucleus or cell | |
JPH10506395A (en) | Bilayer stabilizing components and their use for forming programmable fusogenic liposomes | |
JP2001511440A (en) | Stable granular composite with neutral or negative global charge in layered structure | |
Zhigaltsev et al. | Morphological behavior of liposomes and lipid nanoparticles | |
JPWO2006101201A1 (en) | Liposomes that can efficiently deliver target substances into the nucleus | |
Shangguan et al. | A novel N-acyl phosphatidylethanolamine-containing delivery vehicle for spermine-condensed plasmid DNA | |
Palmer et al. | Transfection properties of stabilized plasmid–lipid particles containing cationic PEG lipids | |
Bernal-Martinez et al. | Reduction-responsive cationic vesicles from bolaamphiphiles with ionizable amino acid or dipeptide polar heads | |
Villanueva et al. | Liposome fusion mediated by hydrophobic magnetic nanoparticles stabilized with oleic acid and modulated by an external magnetic field | |
WO2014030601A1 (en) | Method for producing novel nano-bubble poly-lipo-plex having anionic property | |
WO2020070524A1 (en) | Lipidic drug carriers for cell and organ delivery | |
JPWO2006077857A1 (en) | Method for coating particles with lipid membrane | |
Leung | Biophysical characterization of lipid nanoparticles containing nucleic acid polymers as produced by microfluidic mixing | |
Wasan et al. | Cationic liposome–plasmid DNA complexes used for gene transfer retain a significant trapped volume | |
Gol et al. | Nanocochleates: A novel approach for drug delivery | |
JP2006167521A (en) | New encapsulation technology for genes, etc. using membrane fusion of SUV liposomes |